Evaluating the Safety and Efficacy of Deucravacitinib Compared to Placebo Hidradenitis Suppurativa (HS).

Inclusion Criteria:

• • Male or Female at least 18 -70 years of age

• Able to provide informed consent

• Have at least 5 abscesses and/or inflammatory nodule (AN) count at baselinevisits

• Have HS lesions in 2 distinct anatomical areas

• Women of Childbearing potential must have a negative serum urine pregnancy testat screening and a negative urine pregnancy test at baseline -- prior toadministration of the first dose of study medication

• Women of childbearing potential must be willing to continue a highly effectivemethod of birth control throughout the study (oral, injected or implantedhormonal methods of contraception; placement of an intrauterine device orintrauterine system; barrier methods: condom or occlusive cap (diaphragm orcervical/vault caps) plus spermicidal foam/gel/film/cream/suppository (ifavailable in their locale); male partner sterilization (the vasectomizedpartner should be the sole partner for that participant); true abstinence (whenthis is in line with the preferred and usual lifestyle of the participant).

• Tuberculosis Screening

• Negative IGRA screening for tuberculosis within 3 months prior toscreening, OR

• If a positive history of latent tuberculosis:

• Currently receiving treatment for latent TB per standard of care (with at least 4weeks of treatment prior to baseline visit)

• Have documentation of having completed treatment within 5 years prior to baseline •Agree not to have a live vaccination during the study

Exclusion Criteria:

• • Any other active skin disease that in the opinion of the investigator wouldinterfere with the assessment of HS

• Have greater than 20 draining fistula at baseline

• Receipt of non-biologic treatments for HS within 4 weeks prior to baselineother than antibiotics or hormonal therapy

• Receipt of TNF agents (i.e. Infliximab, adalimumab) or other biologics within 6weeks prior to baseline

• Receipt of new hormonal therapy for HS within 3 weeks prior to baseline

• Receipt of oral antibiotics within 3 weeks prior to baseline.o NOTE: subjects on concomitant antibiotics with a stable dose for 4 weeksprior to baseline visit may be included in the study. Only 25% of totalenrollment may be on concomitant antibiotics.

• Receipt of intralesional kenalog injections within 2 weeks prior to baseline

• Receipt of topical steroids or topical antibiotics for HS for 2 weeks prior tobaselineo NOTE: subjects may continue topical washes (benzoyl peroxide, chlorhexidine,zinc pyrithione, dilute bleach)

• Receipt of opioid analgesics or other concomitant analgesics for HS pain within 72 hours prior to the baseline visito Concomitant use of non-opioid analgesics for treatment of chronic non-HS painis allowed as long as the dose has been stable for 14 days prior to baselineand expected to remain constant throughout the study

• Any uncontrolled diagnosis or condition that in the opinion of the investigatorwill interfere with the assessments or the study.

• Currently has a malignancy or a history of a malignancy within 5 years beforescreen (except successfully treated non-melanoma skin cancer or cervicalcarcinoma in situ)

• History of an ongoing, chronic or recurrent infectious disease

• Are currently pregnant, breastfeeding, or planning to get pregnant during thestudyo male participants who are actively trying to conceive with their partner arealso excluded.

• Previous hypersensitivity reaction to deucravacitinib or to any of thecomponents

• Known allergy to tetracycline antibiotics

• Known infection with HIV, hepatitis B or hepatitis C at screening orrandomization. Patients who are Hepatitis B Core antibody and/or Hep B SurfaceAntigen positive will be excluded from this study. Patients who are Hepatitis Cab positive will also be excluded from this study.

• Underlying condition (including, but not limited to metabolic, hematologic,renal, hepatic, pulmonary, neurologic, endocrine, cardiac, infectious orgastrointestinal) which in the opinion of the investigator significantlyimmunocompromises the subject and/or places the subject at unacceptable riskfor receiving an immunomodulatory therapy